You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Original Contributions Determinants of the Timing of Symptomatic Treatment in Early Parkinson Disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience
Sotirios A. Parashos; Christopher J. Swearingen; Kevin M. Biglan; Ivan Bodis-Wollner; Grace S. Liang; G. Webster Ross; Barbara C. Tilley; Lisa M. Shulman; for the NET-PD Investigators
Arch Neurol 2009; 66: 1099-1104.
[Abstract][Full text][PDF]
Original Contributions Treatment of Neuromyelitis Optica With Mycophenolate Mofetil: Retrospective Analysis of 24 Patients
Anu Jacob; Marcelo Matiello; Brian G. Weinshenker; Dean M. Wingerchuk; Claudia Lucchinetti; Elizabeth Shuster; Jonathan Carter; B. Mark Keegan; Orhun H. Kantarci; Sean J. Pittock
Arch Neurol 2009; 66: 1128-1133.
[Abstract][Full text][PDF]
Observations Nineteen Episodes of Recurrent Myelitis in a Woman With Neuromyelitis Optica and Systemic Lupus Erythematosus
Sajjad Nasir; Douglas A. Kerr; Julius Birnbaum
Arch Neurol 2009; 66: 1160-1163.
[Abstract][Full text][PDF]
Original Contributions Enhancement of Chemokine Expression by Interferon Beta Therapy in Patients With Multiple Sclerosis
Sabine Cepok; Herbert Schreiber; Steve Hoffmann; Dun Zhou; Oliver Neuhaus; Gloria von Geldern; Sonja Hochgesand; Stefan Nessler; Veith Rothhammer; Michael Lang; Hans-Peter Hartung; Bernhard Hemmer
Arch Neurol 2009.138.
[Abstract][Full text][]
Original Contributions Human NARP Mitochondrial Mutation Metabolism Corrected With -Ketoglutarate/Aspartate: A Potential New Therapy
Gianluca Sgarbi; Gabriella A. Casalena; Alessandra Baracca; Giorgio Lenaz; Salvatore DiMauro; Giancarlo Solaini
Arch Neurol 2009; 66: 951-957.
[Abstract][Full text][PDF]
Original Contributions Genome-wide Scan of 500 000 Single-Nucleotide Polymorphisms Among Responders and Nonresponders to Interferon Beta Therapy in Multiple Sclerosis
Manuel Comabella; David W. Craig; Carlos Morcillo-Suárez; Jordi Río; Arcadi Navarro; Marta Fernández; Roland Martin; Xavier Montalban
Arch Neurol 2009; 66: 972-978.
[Abstract][Full text][PDF][ eTable ]
Observations Depletion of B Lymphocytes From Cerebral Perivascular Spaces by Rituximab
Maria del Pilar Martin; Petra D. Cravens; Ryan Winger; Bernd C. Kieseier; Sabine Cepok; Todd N. Eagar; Scott S. Zamvil; Martin S. Weber; Elliot M. Frohman; Betty K. Kleinschmidt-DeMasters; Thomas J. Montine; Bernhard Hemmer; Christina M. Marra; Olaf Stüve
Arch Neurol 2009; 66: 1016-1020.
[Abstract][Full text][PDF]
Images in Neurology Human Immunodeficiency Virus Encephalopathy: Cognitive and Radiologic Improvement After Antiretroviral Therapy
Marcus Tulius T. Silva; Sandra Wagner; Beatriz Grinsztejn
Arch Neurol 2009; 66: 1040-1041.
[Extract][Full text][PDF]
Original Contributions Determinants of the Timing of Symptomatic Treatment in Early Parkinson Disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience
Sotirios A. Parashos; Christopher J. Swearingen; Kevin M. Biglan; Ivan Bodis-Wollner; Grace S. Liang; G. Webster Ross; Barbara C. Tilley; Lisa M. Shulman; for the NET-PD Investigators
Arch Neurol 2009.159.
[Abstract][Full text][]
Neurological Reviews Emerging Therapies for Relapsing Multiple Sclerosis
-Ketoglutarate/Aspartate: A Potential New Therapy